Education and Training
Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation
The purpose of the study is to determine if the use of activated T cells can effectively treat relapsed disease following allogeneic hematopoietic cell transplantation without causing GVHD.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Cytokine Induced Killer Cells
Eligibility
Inclusion Criteria:- Evidence of recurrent or persistent hematologic malignancy following
HLA matched allogeneic hematopoietic cell transplant
- eligible for DLI
- no evidence of GVHD
- stable immunosuppressive regimen
- adequate renal and liver function Exclusion Criteria:- CML patients who have not
received DLI, active infections
Ages Eligible for Study
18 Years - 75 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
BMT Referrals
6507230822
Not Recruiting